Field performance evaluation of the GenBody ConfiSign HIV self-test for blood-based HIV screening in Uganda
- 1National Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda
- 2Makerere University, College of Health Sciences, Kampala, Uganda
- 3Ministry of Health, AIDS Control Program, Kampala, Uganda
Abstract
HIV self-testing (HIVST) is a crucial strategy to reach the UNAIDS 95-95-95 targets by increasing testing coverage in high-burden areas like Uganda. The ConfiSign HIV Self-Test, a blood-based, direct-sampling, vertical flow, single-use rapid test, demonstrated perfect sensitivity and specificity during laboratory validation. This study assessed its performance and operational characteristics in the field compared to the Wondfo HIV Self-Test, which served as the standard of care. A cross-sectional mixed-methods study was conducted from 09 April 2025 to 30 May 2025 at 15 health facilities in Uganda. Participants (n = 2,434, aged ≥14 years) performed self-testing with ConfiSign and Wondfo (standard of care) under observation. Diagnostic accuracy was calculated against Wondfo. Usability, acceptability, and feasibility were evaluated via questionnaires (n = 798 for usability/acceptability; n = 90 for feasibility). Discordant results were resolved using ELISA and PCR. Participants were predominantly female (61.7%) and aged 18−29 (51.8%). ConfiSign positivity was 6.2% versus 6.0% for Wondfo. Sensitivity was 100%, specificity 99.8% (95% CI: 99.53–99.93). Three discordant results were resolved as negative via PCR and ELISA. Usability was high, with 94.7% of users finding components easy to handle and 83.3% collecting samples without difficulty. Acceptability was strong, as 98.0% would reuse the test and 99.0% would recommend it. Feasibility assessments across operational, usability, performance, economic, and acceptability domains yielded positive scores, supporting integration into Uganda’s HIV testing framework. These findings confirm the kit’s diagnostic accuracy and ease of use in field settings, supporting its adoption for HIVST in Uganda. We suggest improvements such as instructions in the local language and the inclusion of additional gauze for better acceptance.
Related
- Evaluation of the Leptocheck-WB IgM Rapid Test for Acute Leptospirosis Among Acute Undifferentiated Fever Patients in Hoima, Western Uganda: Very Low Sensitivity in a Setting Where Non-Icterohaemorrhagiae Leptospira Serogroups Predominate.
- Surfactant Compatibility Screening Improves Formulation Performance of Metarhizium anisopliae for Control of the Tomato Leafminer Phthorimaea absoluta
- Crop-Level Screening and Physiological Evaluation Reveal Drought-Protective Effects of Plant-Derived Extracts in Cucumber Seedlings
- Screening and characterization of endophytic bacterial isolates associated with Echinops kebericho M. and Lepidium sativum L. and evaluation of their potential role
- Exploring the feasibility, acceptability and impact of genomic newborn screening for rare diseases in England: A study protocol for the Generation Study - Process and Impact Evaluation (Version 2)
BibTeX
@article{kyokushaba2026field,
title = {{Field performance evaluation of the GenBody ConfiSign HIV self-test for blood-based HIV screening in Uganda}},
author = {Judith Kyokushaba and Dennis Mujuni and Viola Kasone and Aida Namakula and Caroline Makoha and Flaviano Mugalula and Christopher Okiira and Wilson Nyegenye and Christine Katusiime and Robert Mutumba and Susan Nabadda},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0361282},
url = {https://doi.org/10.1371/journal.pone.0361282},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Field performance evaluation of the GenBody ConfiSign HIV self-test for blood-based HIV screening in Uganda
AU - Judith Kyokushaba
AU - Dennis Mujuni
AU - Viola Kasone
AU - Aida Namakula
AU - Caroline Makoha
AU - Flaviano Mugalula
AU - Christopher Okiira
AU - Wilson Nyegenye
AU - Christine Katusiime
AU - Robert Mutumba
AU - Susan Nabadda
PY - 2026
DA - 2026/10/27
JO - PLOS One
DO - 10.1371/journal.pone.0361282
UR - https://doi.org/10.1371/journal.pone.0361282
AB - HIV self-testing (HIVST) is a crucial strategy to reach the UNAIDS 95-95-95 targets by increasing testing coverage in high-burden areas like Uganda. The ConfiSign HIV Self-Test, a blood-based, direct-sampling, vertical flow, single-use rapid test, demonstrated perfect sensitivity and specificity during laboratory validation. This study assessed its performance and operational characteristics in the field compared to the Wondfo HIV Self-Test, which served as the standard of care. A cross-sectional mixed-methods study was conducted from 09 April 2025 to 30 May 2025 at 15 health facilities in Uganda. Participants (n = 2,434, aged ≥14 years) performed self-testing with ConfiSign and Wondfo (standard of care) under observation. Diagnostic accuracy was calculated against Wondfo. Usability, acceptability, and feasibility were evaluated via questionnaires (n = 798 for usability/acceptability; n = 90 for feasibility). Discordant results were resolved using ELISA and PCR. Participants were predominantly female (61.7%) and aged 18−29 (51.8%). ConfiSign positivity was 6.2% versus 6.0% for Wondfo. Sensitivity was 100%, specificity 99.8% (95% CI: 99.53–99.93). Three discordant results were resolved as negative via PCR and ELISA. Usability was high, with 94.7% of users finding components easy to handle and 83.3% collecting samples without difficulty. Acceptability was strong, as 98.0% would reuse the test and 99.0% would recommend it. Feasibility assessments across operational, usability, performance, economic, and acceptability domains yielded positive scores, supporting integration into Uganda’s HIV testing framework. These findings confirm the kit’s diagnostic accuracy and ease of use in field settings, supporting its adoption for HIVST in Uganda. We suggest improvements such as instructions in the local language and the inclusion of additional gauze for better acceptance.
SN - 1932-6203
ER -